Tumor Volume Changes on 1.5 Tesla Endorectal MRI During Neoadjuvant Androgen Suppression Therapy for Higher-Risk Prostate Cancer and Recurrence in Men Treated Using Radiation Therapy Results of the Phase II CALGB 9682 Study

International Journal of Radiation Oncology Biology Physics

Volumn 71, Issue 1, 2008, Pages 9-15

  D'Amico, Anthony V ^a   Halabi, Susan ^b   Tempany, Clare ^a   Titelbaum, David ^a   Philips, George K ^c   Loffredo, Marian ^a   McMahon, Elizabeth ^a   Sanford, Ben ^b   Vogelzang, Nicholas J ^d   Small, Eric J ^e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d Las Vegas Sun   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Androgen suppression therapy; Magnetic resonance imaging; Prostate cancer; Radiation therapy

Indexed keywords

MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; RADIOTHERAPY; REGRESSION ANALYSIS; RISK ANALYSIS; TUMORS;

ANDROGEN SUPPRESSION THERAPY; HORMONE REFRACTORY PROSTATE CANCER (HRPC); LOCAL THERAPY; PROSTATE CANCER;

ONCOLOGY;

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN THERAPY; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; TUMOR VOLUME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECTUM; REGRESSION ANALYSIS; TIME FACTORS; TUMOR BURDEN;

EID: 41749088915     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.09.033     Document Type: Article

References (24)

1. Rifkin M.D., Zerhouni E.A., Gatsonis C.A., et al. Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. New Engl J Med 323 (1990) 621-626
2. Huzjan R., Sala E., and Hricak H. Magnetic resonance imaging and magnetic resonance spectroscopic imaging of prostate cancer. Nat Clin Pract Urol 2 (2005) 434-442
3. Wang L., Hricak H., Kattan M.W., et al. Prediction of organ-confined prostate cancer: Incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology 238 (2006) 597-603
4. Nakashima J., Tanimoto A., Imai Y., et al. Endorectal MRI for prediction of tumor site, tumor size, and local extension of prostate cancer. Urology 64 (2004) 101-105
5. Villers A., Puech P., Mouton D., et al. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol 176 (2006) 2432-2437
6. Beahrs O.H., Henson D.E., Hutter R.V.P., et al. American Joint Committee on Cancer Staging Manual. 4th ed. (1992), Lippincott, Philadelphia p. 181-186
7. Tempany C.M.C., Zhou X., Zerhouni E., et al. Staging of prostate cancer MRI: Results of Radiology Diagnostic Oncology Group project comparison of three MR imaging techniques. Radiology 192 (1994) 47-54
8. Cheng D., and Tempany C.M. MR imaging of the prostate and bladder. Semin Ultrasound CT MR 19 (1998) 67-89
9. D'Amico A.V., Chang H.E., Garnick M., et al. Tumor volume changes on endorectal coil MRI during neoadjuvant androgen suppression: A new predictor of tumor response. Urology 51 (1998) 287-292
10. Cox J.D., Gallagher M.J., Hammond E.H., et al. Consensus statements on radiation therapy of prostate cancer: Guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol 17 (1999) 1155-1165
11. Roach III M., Hanks G., Thames Jr. H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
12. Cox D.R. Regression models and life tables. J Royal Stat Soc B 34 (1972) 187-220
13. Kaplan E.L., and Meier P. Non-parametric estimation from incomplete observations. J Amer Stat Assoc 53 (1958) 457-500
14. In: Agresti A. (Ed). An introduction to categorical data analysis. 2nd ed. (2002), John Wiley & Sons, New York 16-52
15. Tannock I.F., de Wit R., Berry W.R., et al. Tax 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
16. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
17. D'Amico A.V., Moul J., Carroll P., et al. Surrogate marker for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Natl Cancer Inst 95 (2003) 1376-1383
18. Freedland S.J., Humphreys E.B., Mangold L.A., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 (2005) 433-439
19. Kwak C., Jeong S.J., Park M.S., et al. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J Urol 168 (2002) 995-1000
20. Morote J., Trilla E., Esquena S., et al. Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer. Int J Cancer 108 (2005) 877-891
21. Hussain M., Tangen C.M., Higano C., et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 24 (2006) 3984-3990
22. Zelefsky M.J., Lyass O., Fuks Z., et al. Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy. J Clin Oncol 16 (1998) 3380-3385
23. D'Amico A.V., McLeod D.G., Carroll P.R., et al. Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality. Cancer 109 (2007) 1290-1295
24. Mostaghel E.A., Page S.T., Lin D.w., et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: Therapeutic implications for castration-resistant prostate cancer. Cancer Res 67 (2007) 5033-5041